Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
作者： Liansheng Li , Katrina Chan , Yi Liu , Pingda Ren , Troy Edward Wilson
DOI:
关键词: Kinase activity 、 Chemistry 、 Biochemistry
摘要: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these for treating diseases conditions associated with activity are described herein.
google.co.za 参考文章(700)
Stephen G Ward, John G Foster, Stephanie J Harris, PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Current opinion in investigational drugs. ,vol. 10, pp. 1151- 1162 ,(2009)
Peter K. Vogt, Jonathan R. Hart, Marco Gymnopoulos, Hao Jiang, Sohye Kang, Andreas G. Bader, Li Zhao, Adam Denley, Phosphatidylinositol 3-Kinase: The Oncoprotein Current Topics in Microbiology and Immunology. ,vol. 347, pp. 79- 104 ,(2010) , 10.1007/82_2010_80
Marays Veliz, Javier Pinilla-Ibarz, Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control. ,vol. 19, pp. 37- 53 ,(2012) , 10.1177/107327481201900105
Otto-Henning Wilhelms, Androniki Roesch, Wolfgang Schaumann, Wolfgang Kampe, Use of adenosine derivatives as anti-allergic compounds and pharmaceutical compositions containing them ,(1985)
C. Vitali, M. Sciuto. S. Bombardieri, Immunotherapy in Rheumatoid Arthritis: A Review The International Journal of Artificial Organs. ,vol. 16, pp. 196- 200 ,(1993) , 10.1177/039139889301605S44
Ashley Haase, Michel Brahic, Linda Stowring, Hubert Blum, Detection of Viral Nucleic Acids by in Situ Hybridization Methods in Virology. ,vol. 7, pp. 189- 226 ,(1984) , 10.1016/B978-0-12-470207-3.50013-9
Veronica Campbell, Ryan Thompson, Vivian Villegas, Jennifer Proctor, Karen McGovern, Jeffery L. Kutok, Howard M. Stern, The Potent PI3K-δ,γ Inhibitor IPI-145 Exhibits Differential Activity In Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines Blood. ,vol. 122, pp. 1832- 1832 ,(2013) , 10.1182/BLOOD.V122.21.1832.1832
Anthony A. Fossa, Use of CRF antagonists and renin-angiotensin system inhibitors ,(2000)
G. Shapiro, E. Kwak, J. Baselga, J. Rodon, C. Scheffold, A. D. Laird, C. Bedell, G. Edelman, Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors Journal of Clinical Oncology. ,vol. 27, pp. 3500- 3500 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.3500
Michael Soth, Nidhi Arora, David Goldstein, Counde O'Yang, Nolan Dewdney, Tobias Gabriel, Roland Billedeau, Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same ,(2005)